Clinical Trials

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas at arcu rhoncus, consectetur lectus id, varius velit. Pellentesque viverra bibendum nunc vitae efficitur. Proin gravida eget mauris eu iaculis. Ut a risus fringilla arcu dictum bibendum. Aenean auctor porta libero a tincidunt.

Palovarotene

The Phase 3 trial is a global, multi-center, open-label (no placebo) trial. Approximately 80 adults and children over 4 years of age with the classic FOP mutation (R206H mutation) will be needed to complete the Phase 3 clinical trial. The trial is designed to evaluate whether a daily dosing regimen of palovarotene, with higher doses during times of flare-ups, will reduce the formation of new HO.

Study Status Country Study Type Mutation
Phase 3, Enrolling
  • United States
  • Canada
  • France
  • Spain
  • United Kingdom
Interventional (with drug) R206H
Learn More

REGN2477

The REGN2477 Phase 2 trial is a global, multi-center, placebo controlled trial. Up to 40 adults 18 years of age or older with the classic FOP mutation (R206H mutation) will be needed to complete the Phase 2 clinical trial. The trial is designed to evaluate the safety of REGN2477, and whether monthly dosing of drug will reduce the formation of new HO.

Study Status Country Study Type Mutation
Phase 2, Enrolling
  • United States
  • Italy
  • Netherlands
  • United Kingdom
Interventional (with drug) R206H
Learn More

Make a Difference

Donate Connect Fundraise

Already a Member? Sign In

Sign Up for FOP Connection, Our Monthly eNewsletter